{"entity":{"id":"nct05722015","kind":"trial","name":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77)","aka":[],"tldr":"A phase 3 trial of Pemetrexed, Cisplatin, Carboplatin in non-small-cell lung cancer and small-cell lung cancer, run by Merck Sharp & Dohme LLC, active and no longer recruiting.","summary":"A Study of Subcutaneous (SC) Pembrolizumab Coformulated With Berahyaluronidase Alfa (MK-3475A) vs Intravenous Pembrolizumab in Adult Participants With Metastatic Non-small Cell Lung Cancer (NSCLC) (MK-3475A-D77) is a phase 3 interventional study registered as NCT05722015 by Merck Sharp & Dohme LLC, with 377 participants enrolled, started 2023-02-14 and due to reach its primary completion in 2024-07-12. Interventions recorded: Pembrolizumab Formulated with Berahyaluronidase Alfa, Pemetrexed, Cisplatin, Carboplatin, Paclitaxel. Conditions listed: Metastatic Non-small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2025; the figures recorded here are the registry's, not a publication's.","status":"active","asOf":"2026-09-22","links":[{"label":"ClinicalTrials.gov NCT05722015","url":"https://clinicaltrials.gov/study/NCT05722015"}],"tags":["ctgov-ingest"],"related":[],"cancers":["nsclc","sclc"],"sections":[],"technologies":["checkpoint-inhibitor"],"targets":[],"drugs":["pemetrexed","cisplatin","carboplatin","paclitaxel","pembrolizumab","filgrastim"],"companies":["merck"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":["paper-nct05722015-ann-oncol-2025"],"journals":[],"dependsOn":[],"notes":[],"nct":"NCT05722015","phase":"3","setting":"A Phase 3 Randomized, Open-label Clinical Study to Evaluate the Pharmacokinetics and Safety of Subcutaneous Pembrolizumab Coformulated With Hyaluronidase (MK-3475A) Versus Intravenous Pembrolizumab, Administered With Chemotherapy, in the First-line Treatment of Participants With Metastatic Non-small Cell Lung Cancer","sponsor":"Merck Sharp & Dohme LLC","started":"2023-02-14","startedType":"actual","yearReported":2025,"enrolled":377,"enrolledBasis":"registry","outcomes":[{"endpoint":"Cycle 1: Area Under the Curve From Time 0 to 6 Weeks (AUC0-6 Weeks) of Pembrolizumab After the First Dose","primary":true,"unit":"μg·day/ml","arms":[{"name":"Arm 1: Pembrolizumab Formulated With Berahyaluronidase Alfa + Platinum Doublet Chemotherapy","n":245,"value":1633.24,"note":"geometric CV 40.41%; Figures from the ClinicalTrials.gov results section (first posted 2025-07-28), not from a publication"},{"name":"Arm 2: Pembrolizumab + Platinum Doublet Chemotherapy","n":126,"value":1437.58,"note":"geometric CV 26.23%"}],"p":"<0.00001","source":"https://clinicaltrials.gov/study/NCT05722015?tab=results"}]},"route":"/trials/nct05722015/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"},{"id":"sclc","kind":"cancer","name":"Small-cell lung cancer","route":"/cancers/sclc/"}],"technology":[{"id":"checkpoint-inhibitor","kind":"technology","name":"Immune checkpoint inhibitors","route":"/technologies/checkpoint-inhibitor/"}],"drug":[{"id":"carboplatin","kind":"drug","name":"Carboplatin","route":"/drugs/carboplatin/"},{"id":"cisplatin","kind":"drug","name":"Cisplatin","route":"/drugs/cisplatin/"},{"id":"filgrastim","kind":"drug","name":"Filgrastim (G-CSF)","route":"/drugs/filgrastim/"},{"id":"paclitaxel","kind":"drug","name":"Paclitaxel / nab-paclitaxel","route":"/drugs/paclitaxel/"},{"id":"pembrolizumab","kind":"drug","name":"Pembrolizumab","route":"/drugs/pembrolizumab/"},{"id":"pemetrexed","kind":"drug","name":"Pemetrexed","route":"/drugs/pemetrexed/"}],"company":[{"id":"merck","kind":"company","name":"Merck & Co. (MSD)","route":"/companies/merck/"}],"paper":[{"id":"paper-nct05722015-ann-oncol-2025","kind":"paper","name":"Subcutaneous versus intravenous pembrolizumab, in combination with chemotherapy, for treatment of metastatic non-small-cell lung cancer: the phase III 3475A-D77 trial","route":"/key-papers/paper-nct05722015-ann-oncol-2025/"}]}}